Arnt V Kristen

List of Publications by Year
in descending order

110 papers	9,390 citations	57758 44 h-index	39675 94 g-index
118 all docs	118 docs citations	118 times ranked	7122 citing authors

#	Article	IF	Citations
1	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
2	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
3	Kardiale Beteiligung bei Amyloidose. Springer Reference Medizin, 2022, , 1-12.	0.0	0
4	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	3.0	7
5	A Consolidated Overview Of 14 Years Of Global Data From The Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2022, 28, S111.	1.7	0
6	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
7	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
8	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 91-99.	3.0	8
9	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. Clinical Research in Cardiology, 2021, 110, 579-590.	3.3	3
10	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	1.5	2
11	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World Journal of Cardiology, 2021, 13, 55-67.	1.5	1
12	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
13	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
14	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
15	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
16	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
17	Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms. Vascular Health and Risk Management, 2021, Volume 17, 661-673.	2.3	8
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97

#	Article	IF	Citations
19	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology, 2020, 267, 703-712.	3.6	35
20	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
21	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	3.0	47
22	Amyloid cardiomyopathy. Herz, 2020, 45, 267-271.	1.1	10
23	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	2.6	55
24	Early data on longâ€term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2â€year update from the openâ€label extension of the NEUROâ€TTR trial. European Journal of Neurology, 2020, 27, 1374-1381.	3.3	49
25	Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. Journal of Cardiac Failure, 2020, 26, S82.	1.7	2
26	Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 53.	3.3	25
27	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
28	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
29	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
30	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
31	Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy. Journal of Cardiac Failure, 2019, 25, S9-S10.	1.7	3
32	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica, 2019, 104, 1451-1459.	3.5	29
33	EFFECTS OF PATISIRAN, AN RNA INTERFERENCE THERAPEUTIC, ON REGIONAL LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: THE APOLLO STUDY. Journal of the American College of Cardiology, 2019, 73, 816.	2.8	0
34	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. JAMA Cardiology, 2019, 4, 466.	6.1	68
35	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. Clinical Research in Cardiology, 2019, 108, 1324-1330.	3.3	93
36	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2019, 9, 5-23.	2.2	168

#	Article	IF	Citations
37	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
38	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. Journal of Heart and Lung Transplantation, 2018, 37, 611-618.	0.6	66
39	Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clinical Research in Cardiology, 2018, 107, 158-169.	3.3	50
40	Peak Vâ€™O₂ is an independent predictor of survival in patients with cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 167-173.	3.0	16
41	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 11-21.	27.0	1,944
42	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
43	Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 132-133.	3.0	26
44	Myocardial contraction fraction derived from cardiovascular magnetic resonance cine imagesâ€”reference values and performance in patients with heart failure and left ventricular hypertrophy. European Heart Journal Cardiovascular Imaging, 2017, 18, 1414-1422.	1.2	32
45	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica, 2017, 102, 1424-1431.	3.5	39
46	MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis. Proteomics, 2017, 17, 1700236.	2.2	44
47	Sural nerve injury in familial amyloid polyneuropathy. Neurology, 2017, 89, 475-484.	1.1	48
48	Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis â€“ Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE, 2017, 12, e0173086.	2.5	50
49	Interventional treatment of the left subclavian in 2 patients with coronary steal syndrome. World Journal of Cardiology, 2017, 9, 65.	1.5	3
50	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
51	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
52	Right ventricular long axis strainâ€”validation of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging. European Journal of Radiology, 2016, 85, 1322-1328.	2.6	15
53	Reply. Journal of the American College of Cardiology, 2016, 68, 2494-2495.	2.8	2
54	Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis. Journal of the American Society of Echocardiography, 2016, 29, 1188-1196.	2.8	11

#	Article	IF	Citations
55	Cardiac Amyloid Load. Journal of the American College of Cardiology, 2016, 68, 13-24.	2.8	76
56	RISK STRATIFICATION IN WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS. Journal of the American College of Cardiology, 2016, 67, 1543.	2.8	1
57	Diagnosis of cardiac involvement in systemic amyloidosis by state-of-the-art echocardiography: where are we now?. Expert Opinion on Orphan Drugs, 2016, 4, 639-648.	0.8	1
58	Fast assessment of long axis strain with standard cardiovascular magnetic resonance: a validation study of a novel parameter with reference values. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 69.	3.3	45
59	Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Design, Development and Therapy, 2015, 9, 6319.	4.3	61
60	Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 45-53.	3.0	15
61	Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clinical Research in Cardiology, 2015, 104, 640-647.	3.3	36
62	Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 132-141.	3.0	19
63	Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor. Clinical Research in Cardiology, 2015, 104, 250-257.	3.3	7
64	Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 117-127.	2.4	61
65	In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain, 2015, 138, 549-562.	7.6	112
66	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. Blood, 2015, 126, 1790-1790.	1.4	2
67	Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 202-210.	3.0	15
68	The â€œWagshurst studyâ€• p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 267-275.	3.0	11
69	Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) Tj ETQq1 1 0.784314 rgBT /Ov	0.6	42
70	Skeletal scintigraphy in patients with transthyretin-related amyloidosis. International Journal of Cardiology, 2014, 171, e16-e17.	1.7	1
71	Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 502-510.	5.3	54
72	Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International Journal of Cardiology, 2014, 176, 1113-1115.	1.7	6

#	Article	IF	Citations
73	Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. International Journal of Cardiology, 2013, 164, 179-184.	1.7	37
74	COMPARISON OF LATE GADOLINIUM ENHANCEMENT PATTERNS IN DIFFERENT FORMS OF CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2013, 61, E937.	2.8	0
75	Differences in Transthyretin Amyloidosis between the United States and the Rest of the World: A Report from the Transthyretin Amyloid Outcome Survey (THAOS). Journal of Cardiac Failure, 2013, 19, S69.	1.7	0
76	Inhibition of apoptosis by the intrinsic but not the extrinsic apoptotic pathway in myocardial ischemia-reperfusion. Cardiovascular Pathology, 2013, 22, 280-286.	1.6	22
77	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). Blood, 2013, 122, 1993-1993.	1.4	1
78	Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clinical Research in Cardiology, 2012, 101, 805-813.	3.3	121
79	Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis. Journal of the American College of Cardiology, 2012, 60, 1067-1076.	2.8	253
80	Asymptomatic Sustained Ventricular Fibrillation in a Patient With Left Ventricular Assist Device. Annals of Emergency Medicine, 2011, 57, 25-28.	0.6	49
81	Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood, 2010, 116, 2455-2461.	1.4	109
82	Amyloid in endomyocardial biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 523-532.	2.8	50
83	Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. Journal of Clinical Apheresis, 2010, 25, 315-322.	1.3	17
84	Negative pretransplant serostatus forToxoplasma gondiiis associated with impaired survival after heart transplantation. Transplant International, 2010, 23, 382-389.	1.6	15
85	Acupuncture improves exercise tolerance of patients with heart failure: a placebo-controlled pilot study. Heart, 2010, 96, 1396-1400.	2.9	42
86	High prevalence of amyloid in 150 surgically removed heart valvesâ€"a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovascular Pathology, 2010, 19, 228-235.	1.6	75
87	Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac lightâ€chain amyloidosis. European Journal of Heart Failure, 2009, 11, 1014-1020.	7.1	45
88	Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 187-195.	3.0	47
89	Prevalence of Germline Mutations in the TTR Gene in a Consecutive Series of Surgical Pathology Specimens With ATTR Amyloid. American Journal of Surgical Pathology, 2009, 33, 58-65.	3.7	39
90	Return to Work After Heart Transplantation: Discrepancy With Subjective Work Ability. Transplantation, 2009, 87, 1001-1005.	1.0	22

#	Article	IF	Citations
91	Heart Rate Reduction for 12 Months With Ivabradine Reduces Left Ventricular Mass in Cardiac Allograft Recipients. Transplantation, 2009, 88, 835-841.	1.0	28
92	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. Blood, 2009, 114, 3401-3401.	1.4	1
93	Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transplant International, 2008, 21, 963-971.	1.6	24
94	Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm, 2008, 5, 235-240.	0.7	214
95	Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosisâ˜†. European Journal of Cardio-thoracic Surgery, 2008, 33, 257-262.	1.4	60
96	Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 196-204.	3.0	46
97	Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 129-136.	3.0	1
98	Non-invasive predictors of survival in cardiac amyloidosis. European Journal of Heart Failure, 2007, 9, 617-624.	7.1	109
99	Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 283-287.	3.0	15
100	MR-Relaxometry of Myocardial Tissue. Investigative Radiology, 2007, 42, 636-642.	6.2	57
101	Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-chain Amyloidosis. Journal of Heart and Lung Transplantation, 2007, 26, 1313-1319.	0.6	52
102	Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold-standard. American Journal of Hematology, 2007, 82, 328-328.	4.1	19
103	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	2.4	37
104	Preserved Norepinephrine Reuptake but Reduced Sympathetic Nerve Endings in Hypertrophic Volume-Overloaded Rat Hearts. Journal of Cardiac Failure, 2006, 12, 577-583.	1.7	20
105	Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clinical Research in Cardiology, 2006, 95, 671-674.	3.3	14
106	Indications for Liver Transplantation in Patients with Amyloidosis: A Single-Center Experience with 11 Cases. Transplantation, 2005, 80, S156-S159.	1.0	16
107	Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis. Transplantation, 2005, 80, S160-S163.	1.0	18
108	Risk Stratification in Cardiac Amyloidosis: Novel Approaches. Transplantation, 2005, 80, S151-S155.	1.0	23

#	Article	IF	Citations
109	Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovascular Research, 2005, 67, 283-290.	3.8	29
110	High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. British Journal of Haematology, 2004, 127, 543-551.	2.5	62